Drug Approval | January 31, 2024
Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
The collaboration is focused on overcoming a major limitation in existing cancer drugs
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
